Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

20.340
-0.360-1.74%
Volume:8.57M
Turnover:171.97M
Market Cap:23.15B
PE:-16.19
High:20.540
Open:20.540
Low:19.670
Close:20.700
52wk High:27.360
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:0.67
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.257
ROE:-26.91%
ROA:-14.75%
PB:4.86
PE(LYR):-16.19
PS:6.57

Loading ...

Movement Alert|Zai Lab Falls 5.05% in Regular Trading, Trading at HK$15.3

Market Focus
·
Jul 17

Movement Alert|Zai Lab Rises 5.05% in Regular Trading, Trading at HK$16.19

Market Focus
·
Jul 16

Movement Alert|Zai Lab Falls 5.29% in Regular Trading, Trading at HK$15.05

Market Focus
·
Jul 14

Movement Alert|Zai Lab Rises 5.15% in Regular Trading, Medical Insurance Policy Boost Drives Innovative Drug Sector Higher

Market Focus
·
Jul 10

Movement Alert|Zai Lab Rises 5.09% in Regular Trading, Innovative Drug Sector Broadly Higher on Medical Insurance Policy Tailwinds

Market Focus
·
Jul 08

Zai Lab Director Richard Gaynor Acquires 1,736 Shares for $33,070.8

Reuters
·
Jul 07

Zai Lab grants 2,000 ADS options and 84,893 ADS RSUs under 2024 plan

Bulletin Express
·
Jul 03

Movement Alert|Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment

Market Focus
·
Jun 26

Zai Lab Director William Lis Disposes of 7,040 Shares for $127,353.6

Reuters
·
Jun 25

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Movement Alert|Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound

Market Focus
·
Jun 23

Zai Lab files HKEX next-day disclosure return reporting 3.7 million new shares issued under equity incentive plans

Reuters
·
Jun 22

Zai Lab Ltd Announces Restricted Share Unit Grant

Stock News
·
Jun 22

Zai Lab grants directors 178,968 restricted shares under 2024 equity incentive plan

Reuters
·
Jun 22

Movement Alert|Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock

Market Focus
·
Jun 22

Zai Lab Shares Defy Market Trend with 7% Surge Following European Orphan Drug Designation for Zoci

Stock News
·
Jun 18

Movement Alert|Zai Lab Rises 5.75% in Regular Trading, Institutional Accumulation Filing Disclosed Amid Overnight US Rally

Market Focus
·
Jun 18

Zai Lab shareholders approve 10% share repurchase mandate at annual meeting

Reuters
·
Jun 18

Zai Lab says EMA grants orphan drug status to Zocilurtatug Pelitecan for pulmonary neuroendocrine carcinomas

Reuters
·
Jun 16

Zai Lab Receives Ema Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

THOMSON REUTERS
·
Jun 16